Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA)
Authors:
- Ignasi EstebanIEIgnasi Esteban
- Carmen Pastor-QuiñonesCPCarmen Pastor-Quiñones
- Lorena UseroLULorena Usero
- Elena AurrecoecheaEAElena Aurrecoechea
- Lorenzo FranceschiniLFLorenzo Franceschini
- Arthur EspritAEArthur Esprit
- Josep Lluís GelpíJGJosep Lluís Gelpí
- Francisco Martínez-JiménezFMFrancisco Martínez-Jiménez
- Núria López-BigasNLNúria López-Bigas
- Karine BreckpotKBKarine Breckpot
- Kris ThielemansKTKris Thielemans
- Lorna LealLLLorna Leal
Open Access
Abstract
The COVID-19 pandemic has brought significant changes and advances in the field of vaccination, including the implementation and widespread use of encapsidated mRNA vaccines in general healthcare practice. Here, we present two new mRNAs expressing antigenic parts of the SARS-CoV-2 spike protein and provide data supporting their functionality. The first mRNA, called RBD-mRNA, encodes a trimeric form of the virus spike protein receptor binding domain (RBD). The other mRNA, termed T-mRNA, codes for the relevant HLA I and II spike epitopes. The two mRNAs (COVARNA mRNAs) were designed to be used for delivery to cells in combination, with the RBD-mRNA being the primary source of antigen and the T-mRNA working as an enhancer of immunogenicity by supporting CD4 and CD8 T-cell activation. This innovative approach substantially differs from other available mRNA vaccines, which are largely directed to antibody production by the entire spike protein. In this study, we first show that both mRNAs are functionally transfected into human antigen-presenting cells (APCs). We obtained peripheral blood mononuclear cell (PBMC) samples from three groups of voluntary donors differing in their immunity against SARS-CoV-2: non-infected (naïve), infected-recovered (convalescent), and vaccinated. Using an established method of co-culturing autologous human dendritic cells (hDCs) with T-cells, we detected proliferation and cytokine secretion, thus demonstrating the ability of the COVARNA mRNAs to activate T-cells in an antigen-specific way. Interestingly, important differences in the intensity of the response between the infected-recovered (convalescent) and vaccinated donors were observed, with the levels of T-cell proliferation and cytokine secretion (IFNγ, IL-2R, and IL-13) being higher in the vaccinated group. In summary, our data support the further study of these mRNAs as a combined approach for future use as a vaccine.Keywords
Funding Information
- Spanish Ministry of Economy (MINECO) (SAF-2017-88089-R, RTI2018-096309-B-I00, RD16/0025/0002, RD16/0025/0014-ISCIII-FEDER, FIS PI18/00699, COV20/00214, FIS PI22/00814, ICI20/00067, SGR 615, SGR 653, FP7-HEALTH-2013-INNOVATION-1, 602570-2, H2020-SC1-2016-2017, H2020-SC1-2016-RTD, 731626-HIVACAR)
- Fondo Europeo para el Desarrollo Regional (FEDER) (SAF-2017-88089-R, RTI2018-096309-B-I00, RD16/0025/0002, RD16/0025/0014-ISCIII-FEDER, FIS PI18/00699, COV20/00214, FIS PI22/00814, ICI20/00067, SGR 615, SGR 653, FP7-HEALTH-2013-INNOVATION-1, 602570-2, H2020-SC1-2016-2017, H2020-SC1-2016-RTD, 731626-HIVACAR)
- Spanish AIDS Research Network (SAF-2017-88089-R, RTI2018-096309-B-I00, RD16/0025/0002, RD16/0025/0014-ISCIII-FEDER, FIS PI18/00699, COV20/00214, FIS PI22/00814, ICI20/00067, SGR 615, SGR 653, FP7-HEALTH-2013-INNOVATION-1, 602570-2, H2020-SC1-2016-2017, H2020-SC1-2016-RTD, 731626-HIVACAR)
- Instituto de Salud Carlos III (ISCIII) (SAF-2017-88089-R, RTI2018-096309-B-I00, RD16/0025/0002, RD16/0025/0014-ISCIII-FEDER, FIS PI18/00699, COV20/00214, FIS PI22/00814, ICI20/00067, SGR 615, SGR 653, FP7-HEALTH-2013-INNOVATION-1, 602570-2, H2020-SC1-2016-2017, H2020-SC1-2016-RTD, 731626-HIVACAR)
- Centres de Recerca de Catalunya (SAF-2017-88089-R, RTI2018-096309-B-I00, RD16/0025/0002, RD16/0025/0014-ISCIII-FEDER, FIS PI18/00699, COV20/00214, FIS PI22/00814, ICI20/00067, SGR 615, SGR 653, FP7-HEALTH-2013-INNOVATION-1, 602570-2, H2020-SC1-2016-2017, H2020-SC1-2016-RTD, 731626-HIVACAR)
- European Commission (SAF-2017-88089-R, RTI2018-096309-B-I00, RD16/0025/0002, RD16/0025/0014-ISCIII-FEDER, FIS PI18/00699, COV20/00214, FIS PI22/00814, ICI20/00067, SGR 615, SGR 653, FP7-HEALTH-2013-INNOVATION-1, 602570-2, H2020-SC1-2016-2017, H2020-SC1-2016-RTD, 731626-HIVACAR)
This publication has 40 references indexed in Scilit:
- Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)AIDS, 2017
- Interleukin-2: Biology, Design and ApplicationTrends in Immunology, 2015
- A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patientsAnnals of Oncology, 2013
- A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruptionClinical Immunology, 2012
- Lumenal Part of the DC-LAMP Protein Is Not Required for Induction of Antigen-Specific T Cell Responses by Means of Antigen-DC-LAMP Messenger RNA-Electroporated Dendritic CellsHuman Gene Therapy, 2010
- The Biology of Interleukin-2Annual Review of Immunology, 2008
- Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNAImmunity, 2005
- Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II MoleculesThe Journal of Immunology, 2004
- Natural Truncation of the Chemokine MIP-1β/CCL4 Affects Receptor Specificity but Not Anti-HIV-1 ActivityJournal of Biological Chemistry, 2002
- Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8 + T CellsScience, 1995